Cullinan Therapeutics Inc.
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Cullinan Therapeutics Inc.
RECRUITINGPhase 1NCT07041099
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
Sponsor: Cullinan Therapeutics Inc.Enrolling: 3611 locations
SjögrenSjogren DiseaseSjogren's Syndrome
RECRUITINGPhase 1NCT06994143
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
Sponsor: Cullinan Therapeutics Inc.Enrolling: 372 locations
Rheumatoid Arthritis (RA
RECRUITINGPhase 1NCT06613360
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus...
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Sponsor: Cullinan Therapeutics Inc.Enrolling: 2415 locations
SLESLE (Systemic Lupus)